EGFR and non-small cell lung carcinoma: We observed a significantly higher B cell abundance in the EGFR-mutated NSCLC patients from TCGA (Wilcoxon’s rank sum test P = 0.007, Fig. 4f) further connecting an inflammatory microenvironments with accumulated EGFR mutations.